Background: Drug-drug interactions with insulin secretagogues are associated with increased risk of serious hypoglycemia in patients with type 2 diabetes. We aimed to systematically screen for drugs that interact with the five most commonly used secretagogues-glipizide, glyburide, glimepiride, repaglinide, and nateglinide-to cause serious hypoglycemia. Methods: We screened 400 drugs frequently coprescribed with the secretagogues as candidate interacting precipitants. We first predicted the drug-drug interaction potential based on the pharmacokinetics of each secretagogue-precipitant pair. We then performed pharmacoepidemiologic screening for each secretagogue of interest, and for metformin as a negative control, using an administrative claims database and the self-controlled case series design. The overall rate ratios (RRs) and those for four predefined risk periods were estimated using Poisson regression. The RRs were adjusted for multiple estimation using semi-Bayes method, and then adjusted for metformin results to distinguish native effects of the precipitant from a drug-drug interaction.
agents that are inhibitors of the metabolism of sulfonylureas have been found to be associated with increased risk of hypoglycemia among sulfonylurea users. 10 Inhibition of drug metabolism, and that mediated by cytochrome P450 enzymes in particular, is the most common mechanism underlying known, clinically important drug-drug interactions. 11 In a drug-drug interactions occurring via this mechanism, the object drug (e.g., sulfonylureas) is the drug whose metabolism is inhibited, and the precipitant (e.g., anti-infectives) is the drug that inhibits the metabolism of the object drug.
A variety of methods have been used to identify drugdrug interactions. 12 In vitro and in vivo pharmacokinetic studies are now conducted routinely during drug development to examine the potential for interactions. 13 However, these designs are often applied in a small scale involving only few drug pairs, and are limited in the ability to predict the impact of a drug-drug interactions on health outcomes in the settings of complex physiology of actual patients. Because of ethical and sample size considerations, nonexperimental pharmacoepidemiologic studies are a natural choice when examining the associations between drug-drug interactions and adverse health effects. Signal detection algorithms have been developed to screen for putative interactions using spontaneous adverse drug event reports or longitudinal databases. Such studies in general have limited ability to provide insight for biological mechanisms underlying drug-drug interactions. Interaction screening studies 14, 15 using spontaneous adverse drug event reports often suffer from well-recognized limitations of such databases such as reporting bias. 16 Screening studies using longitudinal databases may offer more promise in identifying interactions, but can face the challenge of simultaneous confounding adjustment across a large number of drug pairs. 17 The self-controlled case series design has been shown to have reasonable performance in screening for drug adverse event associations using longitudinal databases. 18 This design appears to be promising in alleviating the issue of confounding for time-invariant factors when screening for drug-drug interactions because each subject implicitly serves as her/his own control.
The various methods that can be used to identify drugdrug interactions are almost always applied separately, leading to a siloed approach to knowledge generation. 12 We therefore sought to develop a translational and systematic approach that hopefully can improve signal detection of drug-drug interactions. This approach consists two parallel componentsa pharmacoepidemiologic component that uses healthcare data to screen for drug-drug interactions with adverse health effects, and a pharmacokinetic component that utilizes existing pharmacological knowledge as a theoretical basis for predicting high-probability interactions. Any drug pairs identified independently by both methods would be expected to be more likely to have both clinical effects and mechanistic background, such that they could be more readily examined in subsequent hypothesis-driven etiologic studies. We explored the application of this approach in screening for drug-drug interactions with five most commonly used secretagogues associated with increased risk of serious hypoglycemia.
METHODS

Data Sources
Clinformatics Data Mart Database 9 (OptumInsight, Eden Prairie, MN) (CDM) is a deidentified database of administrative health claims for members of a large national US commercial insurance plan that included both commercially-insured and Medicare Advantage enrollees. It includes approximately 14 million members at any one time and about 52 million unique members over the study period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) . CDM contains demographic (including self-reported race) and enrollment data, pharmacy claims, and medical claims that provide data on services, procedures, and their accompanying diagnoses. This study was approved by the Institution Review Board of the University of Pennsylvania.
Identification of Candidate Precipitants
From CDM, we identified all oral drugs concomitantly used with any study secretagogue and calculated the cumulative number of concomitant days for each drug. We selected 400 drugs that had the largest numbers of cumulative concomitant days, which collectively accounted for 99% of concomitant exposure to the study secretagogues. These drugs were the precipitants of interest in the subsequent analyses.
Design of Pharmacoepidemiologic Screening Studies
The self-controlled case series design in this study examined the rate of serious hypoglycemia for a patient receiving a secretagogue of interest after initiating versus not receiving a precipitant. This design is readily applicable for screening purpose in that (1) it is highly computationally efficient because it includes only cases; and (2) it inherently controls for confounding by factors that remain constant within an individual over the observation period, such as variables relating to sex, genetics, individual frailty, and severity of underlying diseases. 19 A screening study using metformin as the negative control object drug was also conducted. A negative control object is a drug that is used for similar indications as the object drug under study, but is not believed to interact pharmacologically with the precipitant. 20 Metformin has two properties that made it attractive as a negative control. One is that it is one of the most commonly used antidiabetic agents with a low risk of hypoglycemia. 21 Also, metformin is eliminated unchanged in urine and therefore is not subject to pharmacokinetic interactions with the precipitants through inhibition of cytochromes P450 isoforms.
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Identification of Cases
Cases were apparent new users of a study secretagogue or metformin (referred to as an object hereinafter) who were hospitalized or treated in an emergency department for hypoglycemia (referred to as serious hypoglycemia hereinafter). An apparent new user was defined as an individual having a baseline period of at least 6 months of continuous eligibility before initiation of a therapy. Cases were identified using one of the following International Classification of Diseases 9th Revision Clinical Modification (ICD-9-CM) discharge diagnosis codes in any position on an emergency department claim or the principal position on an inpatient claim: (a) 251.0 (hypoglycemic coma); (b) 251.1 (other specific hypoglycemia); (c) 251.2 (hypoglycemia, unspecified); or (d) 250.8X (diabetes with other specified manifestations), as long as not co-occurring with ≥1 exclusionary diagnosis suggesting manifestations other than hypoglycemia (eTable 1; http://links.lww.com/EDE/B173). This algorithm, which we have used previously, [23] [24] [25] has a positive predictive value of 89% 26 and 78% 27 for the emergency department and inpatient component, respectively.
Defining Observation Time
The observation time of an object drug consisted of days during which cases were exposed to the drug, beginning on the dispensing date of a prescription for the drug and ending with the first occurrence of the following: (a) cessation of use of the drug, plus 7 days for incomplete adherence; (b) disenrollment; (c) the end of the database; or (d) a dispensed prescription for another secretagogue, including those not of interest in this study. We did not censor on death because CDM does not record death. Observation time from cases who were less than 18 years of age was excluded. For each object-precipitant pair, the observation time was categorized as exposed or unexposed with regard to the exposure to the precipitant. Exposed observation time included person-days during which the case took both the object and the precipitant drug, whereas unexposed observation time included those when the case took the object drug only. Studies have shown that the risk of an adverse event due to a pharmacokinetic drug-drug interaction often peaks shortly after initiating concomitant therapy and declines substantially thereafter. 10, 27, 28 To examine the duration-response relationship of an object-precipitant pair, the exposed observation time was further divided into four risk periods following the initiation of concomitance: 0-10 days, 11-60 days, 61-120 days, and >120 days.
Statistical Analysis
In the primary analysis, we examined the overall risk of serious hypoglycemia over the entire exposed versus unexposed observation time. In the secondary analysis, we examined the risk during the four risk periods. The model specification is described in detail in eAppendix (http://links. lww.com/EDE/B173). Rate ratios (RRs) were estimated using Poisson regression conditioned on individual with a modified version of a SAS macro. 29 To avoid statistically unstable estimates, we did not estimate RRs when there were fewer than five events.
We used a semi-Bayes method to adjust for multiple estimation. The idea behind semi-Bayes adjustment is that the observed variation of the estimated RRs around their geometric mean is larger than the variation of the true but unknown RRs. The semi-Bayes method specifies an a priori value for the variation of the true RRs, which is used to adjust RR estimates. The adjustment shrinks outlying RR estimates toward their geometric mean. This method adjusts for multiple estimation by providing attenuated point estimates and narrower confidence intervals (CIs) than the original, unadjusted estimates. 30, 31 Pearson's correlation coefficients were calculated to examine the correlation between area under concentration-time curve ratio and semi-Bayes-adjusted RRs (RR SB ).
In the adjustment using metformin results, we divided the RR SB for each secretagogue-precipitant pair by the RR SB for the corresponding metformin-precipitant pair, and calculated 95% CIs using the delta method. 32 This adjustment was only applicable to precipitants for which RR SB were estimated with both a secretagogue and metformin. Because the strength of semi-Bayes adjustment varies with the number of precipitants, we therefore performed a separate semi-Bayes adjustment for the subset of precipitants involved in the adjustment using metformin results. All statistical analyses were conducted using SAS v9.4 (SAS Institute Inc., Cary, NC) and the R statistical package, version 3.1.0 (R Development Core Team). Programming code can be found in the eAppendix (http://links.lww.com/EDE/B173).
Pharmacokinetic Prediction
An area under concentration-time curve predicts the ratio of the systemic exposure to an object drug in the presence versus absence of a precipitant. We used the following equation 33, 34 to predict the AUCR of a secretagogue-precipitant pair: 
where f e represents the fraction of the secretagogue excreted unchanged renally, [I] unbound is the unbound plasma concentration of the precipitant, K i,j is the dissociation constant of the precipitant for the jth inhibited cytochrome P450 pathway, and f m,CYPj is the fraction of the secretagogue's hepatic metabolism through the jth inhibited P450 pathway.
[I] unbound and K i,j of the precipitants were ascertained from DrugBank 35 and the published literature. The pharmacokinetic parameters of the secretagogues are shown in eTable 2 (http://links.lww.com/ EDE/B173). As the model for AUCR prediction is sensitive to the input value of f m , we performed sensitivity analyses using f m values obtained from different sources.
Consistent with the US Food and Drug Administration guidelines for assessing clinical drug-drug interactions, secretagogue-precipitant pairs that had AUCRs < 1.25 were considered negligible, those that had 1.25 ≤ AUCR < 2 were considered as weak interactions, those that had 2 ≤ AUCR < 5 were considered as moderate interactions, and those that had AUCR ≥5 were considered strong interactions.
RESULTS
Pharmacoepidemiologic Screening
Characteristics of the cases in pharmacoepidemiologic screening studies are summarized in Table 1 . As meglitinides (i.e., repaglinide and nateglinide) were used less frequently than sulfonylureas and metformin, there were substantially smaller numbers of cases, observed person-days and serious hypoglycemia events for meglitinides. The cases were in general of advanced age. There were more females than males among sulfonylurea and metformin cases, but the opposite was found for meglitinides. These findings were consistent with previous results that females and older adults are at a higher risk of sulfonylurea-induced hypoglycemia. 6, 36 The majority of the cases did not receive any prescription for antidiabetics other than the study secretagogues in the 30 days before events, indicating that concomitant antidiabetic therapy was not materially associated with serious hypoglycemia events.
In the primary analysis that examined the overall rate of serious hypoglycemia during the entire observation time, we identified 140 secretagogue-precipitant pairs associated with increase rates of serious hypoglycemia when used concomitantly. The secondary analysis examined whether the rate of serious hypoglycemia peaked shortly after initiating concomitant therapy and declined thereafter, as one would expect from a pharmacokinetic drug-drug interaction. RR SB and 95% CIs specific to the four predefined risk periods were estimated. The results of these analyses are shown in eFigure 1 and eTable 3 (http://links.lww.com/EDE/B173).
An increased RR SB could be due to true a drug-drug interaction between the secretagogue and the precipitant, to an inherent effect of the precipitant, or to the clinical indication for the precipitant (i.e., the condition for which the precipitant was prescribed). Metformin is rarely expected to interact pharmacokinetically with the precipitants. Even when it does, the drug-drug interaction is not expected to increase the risk of serious hypoglycemia because metformin is rarely 
Pharmacokinetic Prediction
The pharmacokinetic parameter values essential for the prediction were ascertained for 156 precipitants. An area under concentration-time curve was predicted for each drug pair consisting of a study secretagogue and one of the 156 precipitants, resulting in 780 predicted areas under the curve collectively. Consistent with the FDA's guideline for drug-drug interaction studies, 13 25 drug pairs that had 1.25 ≤ AUCR <2 were considered as weak interactions, and nine drug pairs that had 2 ≤ AUCR <5 were considered as moderate interactions (Table 2 ). The areas under the curve of the remaining 746 drug pairs were considered negligible (eTable 3; http://links.lww. com/EDE/B173). Results from the sensitivity analyses using alternative pharmacokinetic parameter values were similar to the findings from the original prediction (eFigure 2; http:// links.lww.com/EDE/B173).
Correlation Between Area Under Concentration-Time Curve and RR SB
Areas under the concentration-time curve and overall RR SB were independently estimated for only 352 and 322 out of 2,000 secretagogue-precipitant pairs before and after adjustment for metformin, respectively. The areas under the curve and overall RR SB , both adjusting and not adjusting for metformin, were poorly correlated (eTables 5, 6; http://links. lww.com/EDE/B173). In addition, the correlation between AUCR and overall RR SB did not decline over time as expected from pharmacokinetic drug-drug interactions.
DISCUSSION
In this study, we attempted to apply a translational approach in screening for clinically important drug-drug interactions with five most commonly used insulin secretagogues. The pharmacoepidemiologic component of this approach identified 140 and 61 secretagogue-precipitant pairs associated with increased overall rates of serious hypoglycemia before and after adjustment with metformin. The pharmacokinetic component predicted 34 drug-drug interactions with the secretagogues based on the existing pharmacologic knowledge. We found that the results from the two components were poorly correlated, such that the supplement of pharmacokinetic prediction did not appear to notably improve signal detection of drug-drug interactions in pharmacoepidemiologic screening in this example.
We were able to replicate the previous findings that the concomitant use of sulfonylureas and cotrimoxazole or gemfibrozil was associated with an increased risk of serious hypoglycemia. 24, 27 The ability to identify known associations demonstrates the robustness of the self-controlled case series design in screening for drug-drug interactions. To our knowledge, this is the first study that adapts this design to screen for drug-drug interactions. Compared with the previous studies that identified interaction signals from spontaneous adverse drug event reports, our study avoids the biases stemming from the use of anecdotal case reports. 14, 15 The pharmacoepidemiologic screening of our study has a few advantages over the drug-drug interaction screening performed by Han et al. 17 that used a cohort design and an electronic healthcare records (EHR) database. First, our screening was more computationally efficient as the self-controlled case series design includes only cases. Second, our study was more efficient in confounding control because this design inherently adjusts for factors that remain constant within individuals. Finally, we used an administrative claims database that usually contains more complete recording of patients' healthcare and enables more accurate exposure measurement as compared with EHR databases.
An important strength of our pharmacoepidemiologic screening was the adjustment using metformin as an explicit negative control object drug. Before the adjustment, macrolides, and quinolones, such as clarithromycin, azithromycin, ciprofloxacin, levofloxacin, and ofloxacin showed consistently increased rates of serious hypoglycemia across all the object drugs including metformin. It is very unlikely that these precipitants interact with all the secretagogues, because the secretagogues differ in their hepatic metabolism profiles. The associations seem more likely due to infection, confounding by indication, and/or the inherent hypoglycemic effects of the precipitants. In fact, quinolones are known to cause dysglycemia. 37, 38 The adjustment using the metformin results largely removed these seemingly spurious associations, suggesting that it is an effective means to reduce false positive signals. Of note, the adjustment also had unintended effects. Because it could only be applied to precipitants for which an RR SB was estimated both with the secretagogues and metformin, the total number of RR SB estimates was reduced after the metformin adjustment. In addition, in few cases, the adjustment inflated the RR SB for secretagogue-precipitant pairs when the corresponding metformin-precipitant pair was associated with a decreased risk of serious hypoglycemia. An example was levothyroxine and sulfonylureas that changed from having no association to being positively associated with serious hypoglycemia with the metformin adjustment.
A limitation of the self-controlled case series design is that it is potentially subject to reverse causality bias, 39 especially for previous known drug-drug interactions. If a precipitant is known to interact with a secretagogue, it may be used less frequently or discontinued after a hypoglycemic event. The RR would then bias away from the null and overestimate the true rate of hypoglycemia of the precipitant. However, considering drug-drug interactions are often overlooked in clinical practice, we doubt that a large proportion of prescribers would attribute an episode of serious hypoglycemia to an interaction and as a result discontinue the precipitant to reduce risk in the future. Reverse causality bias therefore seems to us unlikely to be largely responsible for associations with known drug-drug interactions.
We were surprised to find that the predicted areas under concentration-time curves were poorly correlated with the overall RR SB estimates, considering that inhibition of cytochrome P450s is thought to be the most common mechanism underlying known, clinically important drug-drug interactions. 11 There are at least five potential explanations for the poor correlation. First, a pharmacokinetic drug-drug interaction can result from multiple mechanisms. The model used in the pharmacokinetic prediction was oversimplified as it ignored factors other than competitive inhibition of P450-mediated hepatic metabolism. Compared with sophisticated physiological-based pharmacokinetic models that require customization for each drug pair, the model used in our study is more readily applied to a large number of drug pairs, but is known to be less accurate. 40 In fact, this compromise represents a major methodologic challenge in our study, which is maximizing the throughput by simplifying analyses while maintaining validity.
Second, we did not adjust for time-varying factors that could affect hypoglycemia risk in the analysis of the self-controlled case series design, which was a similar trade-off between accuracy and efficiency. Such adjustment was not feasible because we were analyzing thousands of drug pairs at once. Drugs that are often used together with a precipitant may bias the RRs away from or toward the null if they cause hypoglycemia or hyperglycemia, respectively. Other time-varying factors potentially of concern include dose changes, age, disease progression, and renal and hepatic function. Although the use of metformin as a control mitigated the effects of these sources of potential bias, the estimation of RR SB may have been affected. Third, the model for area under the concentration-time curve prediction ignores concentration-time relationship and only predicts the average magnitude of change in the systemic exposure to a secretagogue. It is therefore unable to predict the highest concentration of a secretagogue in the liver resulting from a drug interaction, which may be more relevant to inducing hypoglycemia.
Fourth, drug-drug interactions may also occur at pharmacodynamic level that potentially can be identified through pharmacoepidemiologic screening but cannot be predicted using area under the concentration-time curve.
Fifth, area under the concentration-time curve and RR SB were both estimated only for a subset of precipitants that may not fully represent the correlation between the two metrics. Many precipitants associated with an increased risk of hypoglycemia lacked in vitro data on their potential for inhibiting the relevant cytochrome P450 enzymes, which precludes area under the concentration-time curve prediction. Atazanavir, ritonavir, and ketoconazole were predicted to interact with the secretagogues. These drugs, however, did not have enough number of events for estimating RR SB , presumably because they were not used, or only used for a short period of time, concomitantly with the secretagogues.
There are several other limitations in our study. They include small numbers of cases and events that hampered our ability to examine drug-drug interactions with meglitinides, lack of pharmacy claims data for over-the-counter drugs, lack of analysis on dose-response relationship, lack of data on adherence to prescribed secretagogues and precipitants, and residual confounding inherent to observational studies. Such limitations are likely to affect other applications of these methods to healthcare databases.
Although in this application pharmacokinetic prediction did not corroborate pharmacoepidemiologic screening, it is important to note that we cannot tell from this single example whether or not the approach of coupling the two methods would work in general. In addition, because we do not know the true interaction status for very many, if any, secretagogueprecipitant pairs, we cannot quantitatively evaluate the performance of either component or use one to evaluate against the other. Further studies are warranted to improve both components thus to improve the overall performance of the approach. For pharmacoepidemiologic screening, future studies are needed to explore adjusting for time-varying factors in the self-controlled case series analysis for a large number of drug pairs. For pharmacokinetic prediction, a framework that allows for high-throughput drug-drug interaction prediction with improved accuracy will be highly desirable.
Pharmacokinetic prediction can be applied to any drug pairs whose relevant pharmacological information is available. The selfcontrolled case series design is well suited to study acute effects of drug exposures. 39 We believe that the design is widely applicable to screen for drug-drug interactions associated with any acute adverse health outcomes identifiable in longitudinal healthcare databases. In theory, the combination of two methods can enable a systematic identification of drug-drug interactions, both pharmacokinetic and pharmacodynamic, that lead to acute adverse health outcomes. Although EHRs have been increasingly used for data mining, we believe that they are less desirable in screening for drug-drug interactions as compared with healthcare claims databases. One reason is that EHRs may not be complete for the data from other physicians or sites of care. Also, EHRs record only prescription orders, which may lead to less accurate ascertainment of drug exposure than claims databases that record prescription dispensations. Hypoglycemia induced by antidiabetic agents is a major clinical and public health concern. Drug-drug interactions causing hypoglycemia are among the main limiting factors in the glycemic management of diabetes. The ultimate goal of research on these interactions is to prevent them from harming patients. Our study helps to achieve this goal by identifying a number of drugs that appear to be associated with increased risk of serious hypoglycemia during concomitant use with the secretagogues. Future studies are needed to confirm or refute these potential associations, to identify high-risk subgroups, and to elucidate the mechanisms underlying true drug-drug interactions involving the secretagogues. Although combining pharmacoepidemiologic screening with pharmacokinetic prediction did not notably improve screening for drug-drug interactions in this study, we believe that on improvement, this translational approach could be useful in systematical identification of drug-drug interactions with both mechanistic understanding and clinical effects.
